avapro has been researched along with Hypertension, Renal in 12 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
Hypertension, Renal: Persistent high BLOOD PRESSURE due to KIDNEY DISEASES, such as those involving the renal parenchyma, the renal vasculature, or tumors that secrete RENIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A substantial number of patients with lupus nephritis (LN) are refractory to conventional glucocorticoid (GC) treatment." | 5.39 | Successful treatment of class IV+V lupus nephritis with combination therapy of high-dose corticosteroids, tacrolimus and intravenous cyclophosphamide. ( Amano, K; Chino, K; Ito, T; Kato, H; Kondo, T; Kurasawa, T; Nagasawa, H; Nishi, E; Nishimura, K; Ogawa, H; Okuyama, A; Sakai, R; Shibata, A; Takei, H, 2013) |
| " Risk factors for diabetic nephropathy are discussed, and include hyperglycemia, hypertension, angiotensin II, proteinuria, dyslipidemia, smoking, and anemia." | 4.82 | Outcome studies in diabetic nephropathy. ( Mohanram, A; Toto, RD, 2003) |
| "When indomethacin was added to enalapril treatment, a further significant reduction in urinary proteins and fractional albumin clearance was observed." | 2.69 | The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. ( Azzollini, N; Mister, M; Perico, N; Remuzzi, A; Remuzzi, G; Ruggenenti, P; Sangalli, F, 1998) |
| "Irbesartan treatment of patients with type 2 diabetes, hypertension, and microalbuminuria may lead to major improvements in long-term patient outcomes, with substantial cost savings as an added bonus to third party payers." | 2.42 | Health economics studies assessing irbesartan use in patients with hypertension, type 2 diabetes, and microalbuminuria. ( Palmer, AJ; Rodby, RA, 2004) |
| "A substantial number of patients with lupus nephritis (LN) are refractory to conventional glucocorticoid (GC) treatment." | 1.39 | Successful treatment of class IV+V lupus nephritis with combination therapy of high-dose corticosteroids, tacrolimus and intravenous cyclophosphamide. ( Amano, K; Chino, K; Ito, T; Kato, H; Kondo, T; Kurasawa, T; Nagasawa, H; Nishi, E; Nishimura, K; Ogawa, H; Okuyama, A; Sakai, R; Shibata, A; Takei, H, 2013) |
| "In captopril-treated HS-2 rats, glomerular filtration rate decline and mortality were significantly blunted as compared with all other groups (50% mortality after week 12)." | 1.33 | Control of hypertension with captopril affords better renal protection as compared with irbesartan in salt-loaded uremic rats. ( Aladjem, M; Averbukh, Z; Berman, S; Cohn, M; Efrati, S; Galperin, E; Modai, D; Rapoport, M; Weissgarten, J, 2005) |
| " Pharmacokinetic-pharmacodynamic (PK/PD) modeling was applied to investigate the pharmacokinetic and pharmacodynamic interaction between irbesartan and HCTZ in renal hypertensive dogs at non-steady-state and steady-state." | 1.33 | Pharmacokinetic and pharmacodynamic interaction between irbesartan and hydrochlorothiazide in renal hypertensive dogs. ( Huang, XH; Li, J; Qiu, FR; Xie, HT, 2005) |
| " In genetic and renal hypertensive rats, the antihypertensive effect induced after acute dosing of SR 47436 was similar to that observed after losartan and enalapril." | 1.29 | Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models. ( Canals, F; Cazaubon, C; Galindo, G; Lacour, C; Nisato, D; Segondy, D, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 9 (75.00) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kurasawa, T | 1 |
| Nagasawa, H | 1 |
| Nishi, E | 1 |
| Takei, H | 1 |
| Okuyama, A | 1 |
| Kondo, T | 1 |
| Nishimura, K | 1 |
| Sakai, R | 1 |
| Shibata, A | 1 |
| Chino, K | 1 |
| Ogawa, H | 1 |
| Ito, T | 1 |
| Amano, K | 1 |
| Kato, H | 1 |
| Recordati, G | 1 |
| Zorzoli, F | 1 |
| Pontara, O | 1 |
| Turolo, L | 1 |
| Zanchetti, A | 1 |
| Eberhard, R | 1 |
| Dikow, R | 1 |
| Rossing, K | 1 |
| Christensen, PK | 1 |
| Andersen, S | 1 |
| Hovind, P | 1 |
| Hansen, HP | 1 |
| Parving, HH | 1 |
| Mohanram, A | 1 |
| Toto, RD | 1 |
| González-Albarrán, O | 1 |
| Gómez, O | 1 |
| Ruiz, E | 1 |
| Vieitez, P | 1 |
| García-Robles, R | 1 |
| Palmer, AJ | 1 |
| Rodby, RA | 1 |
| Weissgarten, J | 1 |
| Berman, S | 1 |
| Efrati, S | 1 |
| Rapoport, M | 1 |
| Modai, D | 1 |
| Cohn, M | 1 |
| Aladjem, M | 1 |
| Galperin, E | 1 |
| Averbukh, Z | 1 |
| Huang, XH | 1 |
| Qiu, FR | 1 |
| Xie, HT | 1 |
| Li, J | 1 |
| Lacour, C | 1 |
| Canals, F | 1 |
| Galindo, G | 1 |
| Cazaubon, C | 1 |
| Segondy, D | 1 |
| Nisato, D | 1 |
| Perico, N | 1 |
| Remuzzi, A | 1 |
| Sangalli, F | 1 |
| Azzollini, N | 1 |
| Mister, M | 1 |
| Ruggenenti, P | 1 |
| Remuzzi, G | 1 |
| Jerums, G | 1 |
| Cooper, ME | 1 |
| Gilbert, RE | 1 |
| Atkins, RC | 1 |
3 reviews available for avapro and Hypertension, Renal
| Article | Year |
|---|---|
Angiotensin receptor antagonists in patients with nephropathy due to type 2 diabetes.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype | 2002 |
Outcome studies in diabetic nephropathy.
Topics: Albuminuria; Anemia; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme | 2003 |
Health economics studies assessing irbesartan use in patients with hypertension, type 2 diabetes, and microalbuminuria.
Topics: Albuminuria; Antihypertensive Agents; Biphenyl Compounds; Cost Savings; Diabetes Mellitus, Type 2; H | 2004 |
2 trials available for avapro and Hypertension, Renal
| Article | Year |
|---|---|
Comparative effects of Irbesartan on ambulatory and office blood pressure: a substudy of ambulatory blood pressure from the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria study.
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Blood Pressur | 2003 |
The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflam | 1998 |
7 other studies available for avapro and Hypertension, Renal
| Article | Year |
|---|---|
Successful treatment of class IV+V lupus nephritis with combination therapy of high-dose corticosteroids, tacrolimus and intravenous cyclophosphamide.
Topics: Adolescent; Antihypertensive Agents; Biphenyl Compounds; Cyclophosphamide; Cyclosporine; Drug Therap | 2013 |
Factors influencing acute ischaemia-induced renal hypertension in rats.
Topics: Acute Disease; Animals; Antihypertensive Agents; Biphenyl Compounds; Diuresis; Hematocrit; Hypertens | 2002 |
Role of systolic blood pressureon the progression of kidney damage in an experimental model of type 2 diabetes mellitus, obesity, and hypertension (Zucker rats).
Topics: Albuminuria; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus | 2003 |
Control of hypertension with captopril affords better renal protection as compared with irbesartan in salt-loaded uremic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihype | 2005 |
Pharmacokinetic and pharmacodynamic interaction between irbesartan and hydrochlorothiazide in renal hypertensive dogs.
Topics: Animals; Biphenyl Compounds; Dogs; Drug Interactions; Drug Therapy, Combination; Hydrochlorothiazide | 2005 |
Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models.
Topics: Administration, Oral; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; | 1994 |
Renal protection by angiotensin II receptor antagonists in patients with type 2 diabetes.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials as Topic; Diab | 2001 |